Insulet (PODD) Profit After Tax Growth (5y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.35% |
| Sep 30, 2025 | 49.83% |
| Jun 30, 2025 | 9.34% |
| Mar 31, 2025 | 79.93% |
| Dec 31, 2024 | 82.31% |
| Sep 30, 2024 | 149.60% |
| Jun 30, 2024 | 166.61% |
| Mar 31, 2024 | 63.56% |
| Dec 31, 2023 | 59.84% |
| Sep 30, 2023 | 98.13% |
| Jun 30, 2023 | 78.38% |
| Mar 31, 2023 | 41.17% |
| Dec 31, 2022 | 34.96% |
| Sep 30, 2022 | -18.48% |
| Jun 30, 2022 | -35.13% |
| Mar 31, 2022 | 36.77% |
| Dec 31, 2021 | 39.01% |
| Sep 30, 2021 | 43.52% |
| Jun 30, 2021 | -41.86% |
| Dec 31, 2020 | -1.45% |
| Sep 30, 2020 | 21.18% |
| Jun 30, 2020 | 23.16% |
| Mar 31, 2020 | 29.24% |
| Dec 31, 2019 | 23.95% |
| Sep 30, 2019 | 15.70% |
| Jun 30, 2019 | 15.42% |
| Mar 31, 2019 | 22.12% |
| Dec 31, 2018 | 42.91% |
| Sep 30, 2018 | 15.77% |
| Jun 30, 2018 | 30.55% |
| Mar 31, 2018 | 9.15% |
| Dec 31, 2017 | 7.62% |
| Sep 30, 2017 | 29.08% |
| Jun 30, 2017 | 11.71% |
| Mar 31, 2017 | 7.56% |
| Dec 31, 2016 | 8.58% |
| Sep 30, 2016 | 25.65% |
| Jun 30, 2016 | 11.65% |
| Mar 31, 2016 | -1.65% |
| Dec 31, 2015 | 5.27% |
| Sep 30, 2015 | -9.36% |
| Jun 30, 2015 | -4.72% |